2Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer randomized controlled study. World J Surg, 1994, 18:150
4Sugarbakor PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum, 1994, 37:115
3[1]Yonemura Y, Sugiyama K, Fushida S, et al. Treatment options for peritoneal dissemination with chemotherapy. In Yonemura Y(eds): Peritoneal dissemination——molecular mechanisms and the latest therapy. Maeda Shoten Co, Ltd Kanazawa, Japan, 1998:175.
4[2]Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon's role. Langenbecks Arch Surg, 1999, 384: 576.
5[3]Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993, 17: 256.
6[4]Yonemura Y, Matsuki N, Sakuma H, et al. Effect of intra-arterial infusion of MMC and CDDP for gastric cancer patients with liver metastasis. Jap J Surg, 1992, 22: 253.
7[5]Ohoyama S. Nakajima S. Ishihara S, et al. FLEP therapy for advanced gastric cancer. In Miyazaki I and Yonemura Y(eds): Treatment strategies for advanced gastric cancer. Soft Science. Tokyo,1995:110.
8[6]Kern W, Brasess J, Samel S, et al. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage in patients with locally advanced gastric cancer. The proceedings of 2nd International Gastric Cancer Congress. 1997: 1387.
9[7]Elias D, Detroz B, Debaeme B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia reliable and unreliable concepts. Hepatogastroenterology, 1994, 41: 207.
10[8]Yonemura Y. Hyperthermochemotherpy for the treatment of peritoneal dissemination. In Yonemura Y, et al. Contemporary approaches toward cure of gastric cancer. Kanazawa: Maeda Shoten Co. Ltd, 1996, 105.
